EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aztreonam-avibactam against carbapenem-resistant Enterobacterales: Susceptibility and genomic analysis in a Chinese teaching hospital

Qiaomin Zhang, Guili Zhang, Hanlian Huang, Xinyi Cao, Zhencheng Fang, Wen Ma, Xiaoyan Dai, Zhongbiao Chen, Hongwei Shen, Peng Li

Journal of Global Antimicrobial Resistance · 2026

DOI: 10.1016/j.jgar.2026.06.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Global Antimicrobial Resistance, 2026. Verfasst von Qiaomin Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory Medical Center, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Aztreonam, Carbapenem-Resistant Enterobacteriaceae, Anti-Bacterial Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Shenzhen Science and Technology Innovation Committee, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate aztreonam-avibactam (AZA) susceptibility and molecular features of carbapenem-resistant Enterobacterales (CRE) at a Shenzhen hospital. METHODS: CRE isolates were collected from January 2018 to September 2025 and analysed by whole-genome sequencing, AZA disk diffusion, and clinical data review. Regional phylogenetic analysis from multiple hospitals in Guangdong Province was conducted. RESULTS: Among 8655 Enterobacterales isolates, 152 (1.8%) were CRE, with prevalence increasing from 0.3% (2018) to 2.5% (2025). Isolates were predominantly carbapenem-resistant Klebsiella pneumoniae (CRKP, n = 79) and Escherichia coli (CREC, n = 43), mainly from the intensive care unit (37.5%) and elderly patients (≥60 y, 55.9%). Ceftazidime-avibactam was 45.4% resistant overall, 91.5% susceptible to blaKPC-CRE, and 100% resistant to blaNDM-CRE. All isolates were susceptible to AZA. CRKP was dominated by the ST11-KL64 clone (46.8%), while CREC was genetically diverse. The blaKPC-2 predominated in CRKP (58.2%) and blaNDM-5 prevailed in CREC (74.4%). Notably, 40 carbapenemase-negative CRE isolates accounted for 26.3% of all CRE isolates during the study period. Key resistance genes in CRKP included rmtB (58.2%), qnrS1 (72.2%), blaCTX-M-65 (48.1%), blaLAP-2 (57.0%), blaSHV-134 (38.0%), and fosA6 (93.7%); those in CREC were dfrA12 (41.9%), floR (58.1%), and mphB (88.4%). Regional phylogeny demonstrated that local CRKP clustered within the provincially dominant ST11-KL64 epidemic clade, while CREC were intermixed with strains across Guangdong Province, indicating widespread regional transmission and multiple independent introduction events. CONCLUSIONS: The rise of CRE driven by ST11-KL64 and a growing proportion of non-carbapenemase producers necessitates strengthened infection control. The universal in vitro AZA susceptibility offers a promising therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Azabicyclo CompoundsAztreonamCarbapenem-Resistant EnterobacteriaceaeAnti-Bacterial AgentsEnterobacteriaceae InfectionsHumansChinaMicrobial Sensitivity TestsHospitals, TeachingWhole Genome SequencingPhylogenyKlebsiella pneumoniaeDrug CombinationsDrug Resistance, Multiple, BacterialCeftazidimeEscherichia coliGenome, BacterialCarbapenemsbeta-Lactamases

Stichwörter der Autor:innen

Aztreonam-avibactamCarbapenem-resistantEnterobacteralesEscherichia coliKlebsiella pneumoniaeWhole-genome sequencing

Substanzen

Azabicyclo CompoundsAztreonamAnti-Bacterial Agentsavibactam, ceftazidime drug combinationDrug CombinationsCeftazidimeCarbapenemsbeta-Lactamasesaztreonam, avibactam drug combination

Autor:innen und Institutionen

  • Clinical Laboratory Medical Center, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
  • Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • School of Food and Drug, Shenzhen Polytechnic University, Shenzhen, Guangdong, China. Electronic address: lipengwd@szpu.edu.cn.

Förderung

  • Guangdong Basic and Applied Basic Research Foundation
  • Shenzhen Science and Technology Innovation Committee
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Q., Zhang, G., Huang, H., Cao, X., Fang, Z., Ma, W., Dai, X., Chen, Z., Shen, H., & Li, P. (2026). Aztreonam-avibactam against carbapenem-resistant Enterobacterales: Susceptibility and genomic analysis in a Chinese teaching hospital. Journal of Global Antimicrobial Resistance. https://doi.org/10.1016/j.jgar.2026.06.024

Vancouver

Zhang Q, Zhang G, Huang H, Cao X, Fang Z, Ma W, et al. Aztreonam-avibactam against carbapenem-resistant Enterobacterales: Susceptibility and genomic analysis in a Chinese teaching hospital. Journal of Global Antimicrobial Resistance. 2026. doi:10.1016/j.jgar.2026.06.024

BibTeX
@article{Zhang2026,
  author = {Zhang, Qiaomin and Zhang, Guili and Huang, Hanlian and Cao, Xinyi and Fang, Zhencheng and Ma, Wen and Dai, Xiaoyan and Chen, Zhongbiao and Shen, Hongwei and Li, Peng},
  title = {Aztreonam-avibactam against carbapenem-resistant Enterobacterales: Susceptibility and genomic analysis in a Chinese teaching hospital},
  journal = {Journal of Global Antimicrobial Resistance},
  year = {2026},
  doi = {10.1016/j.jgar.2026.06.024}
}
Kostenlos starten →